ViewsML will present an AI platform at USCAP 2026 that predicts biomarker expression from standard H&E slides, enabling per-cell spatial analysis without additional staining, according to the company.
As the 2026 ADA Standards of Care emphasize earlier identification and more precise classification of diabetes, clinical laboratories are rethinking workflows, assay menus, and their role in detection.
A proof-of-concept study shows that bacteria-metabolized molecules enriched with carbon-13 produce detectable exhaled CO2, enabling rapid infection identification with inexpensive infrared scanners.
The Vizient Innovative Technology Program evaluates products submitted through client-led councils for their potential to improve clinical care, patient safety, and business operations.
The newly identified aptamers match antibody-level binding strength and could support the development of lower-cost, point-of-care blood tests for neurodegeneration.
